期刊文献+

奥沙利铂联合化疗治疗晚期结肠癌的近期疗效及安全性观察 被引量:8

Observation of the Therapeutic Effect and Toxicity of Oxaliplatin plus 5-FU/CF in the Treatment of Advanced Colorectal Cancer
原文传递
导出
摘要 目的:观察奥沙利铂(L-OHP)联合亚叶酸钙(CF)和氟尿嘧啶(5-FU)方案治疗晚期结肠癌的近期疗效及安全性。方法:经病理组织学诊断的晚期结肠癌50例,随机分为治疗组30例,给予L-OHP+CF+5-FU治疗;对照组20例,给予卡铂+CF+5-FU治疗。21d为1个周期。2个周期评价疗效。结果:治疗组总有效率为50.00%,对照组总有效率为35.00%,2组比较差异有统计学意义(P<0.05);治疗组出现恶心呕吐、骨髓抑制患者少于对照组(P<0.05),但出现神经毒性、手足综合征的患者明显多于对照组(P<0.05)。结论:L-OHP联合CF和5-FU方案治疗晚期结肠癌的近期客观疗效较高,但远期疗效仍需进一步观察;不良反应主要是末梢神经毒性和胃肠道反应。 OBJECTIVE:To evaluate the therapeutic effect and toxicity of oxaliplatin plus 5-FU/CF in the treatment of advanced colorectal cancer.METHODS:50 patients with advanced colorectal cancer were randomly divided into 2 groups,control group 30 patients received L-OHP plus 5-FU/CF.20 cases in the control group received cisplatin plus 5-FU/CF.This regimen was repeated every 21 days.RESULTS:In the treatment group,the total effective rate was 50.00% in the control group,the total effective rate was 35.00%,the difference was statistically significant(P〈0.05),adverse reactions was significant difference between the 2 groups(P〈0.05).CONCLUSION:The combination of oxaliplatin and 5-FU/CF is an effective and tolerable regimen for treatment of advanced colorectal cancer.
出处 《中国药房》 CAS CSCD 北大核心 2011年第4期331-332,共2页 China Pharmacy
关键词 奥沙利铂 晚期结肠癌 近期疗效 安全性 Oxaliplatin Advanced colorectal cancer Short-term effect Safety
  • 相关文献

参考文献6

二级参考文献22

  • 1翟艳辉,李莹,杨朝英,黎苗,董瑜.草酸铂联合氟尿嘧啶、甲酰四氢叶酸治疗晚期大肠癌临床疗效观察[J].现代肿瘤医学,2006,14(1):65-67. 被引量:15
  • 2Lebwohl D,Canetta R.Clinical development of platinum complexes in cancer therapy:an historical perspective and an update[J].Eur J Cancer,1998,34(10):1522-1534. 被引量:1
  • 3Woynarowski JM,Faivre S,Herzing MC,et al.Oxaliplatin-induced damage of cellular DNA[J].Mol Pharmacol,2000,58(5):920-927. 被引量:1
  • 4Woynarowski JM,Chapman WG,Napier C,et al.Sequence-andregion-specificity of oxaliplatin adducts in naked and cellular DNA[J].Mol Pharmacol,1998,54(5):770-777. 被引量:1
  • 5Maindrault Goebel F,de-GramoutA,Louver C,et al.High dose intensity oxaliplation added to the simplified bimonthly leucororin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX)[J].Eur J Cancer,2001,37(8):1000-1005. 被引量:1
  • 6Andre' T,Boni C,Mounedji-Boudiaf L,et al.Oxaliplatin,fluorouracil and leucovorin as adjuvant treatment for colon cancer[J].N Engl J Med,2004,350(23):2362-2374. 被引量:1
  • 7Camp E R,Summy J,Bauer T W,et aI.Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor[J]. Clin Cancer Ees,2005,11(1):397--405. 被引量:1
  • 8Ng M,Ounningham D.Oetuximab(Erbitux)-an emerging targeted therapy for epidermal growth factor receptor-expressing tumours[J].Int J Olin Pract,2004,58(10):970-976. 被引量:1
  • 9Bokemeyer C,Bondarenko I,Makhson A,et al. Oetuximab plus 5-FU/FA/oxalip latin (FOLFOX4) versus FOLFOX4 in the first-line treatment of metAstAtic co]orectal cancer (mCRC):OPUS,a randomized phage II study[J].J Olin Oncol,2007,25(18Suppl).4035-4052. 被引量:1
  • 10Tabernero J,Van Cutaem E,Diaz Eubio E,et al.Phase II trial of cetuximab in combination with fluorouracil,leucovorin,and oxalip latin in the first line treatment ofmetastatic colorectal cancer[J].J Clin Oncol, 2007,25(33): 5225-5252. 被引量:1

共引文献65

同被引文献66

引证文献8

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部